FDA chief to depart after Trump signed off on ousting him

FDA Chief to Depart After Trump Signed Off on Oust

FDA chief to depart after Trump – Food and Drug Administration (FDA) Commissioner Marty Makary is leaving the Trump administration, according to three individuals who have insight into the situation. His resignation followed President Donald Trump’s approval of a plan to remove him last week. The decision marks the latest in a series of leadership changes within the agency, as Makary faced mounting criticism from both within and outside the administration.

Internal and External Pressures

Makary’s departure stemmed from persistent pressure from inside the Trump administration, particularly regarding his stance on flavored e-cigarettes. His refusal to approve the sale of youth-targeted vape flavors had become a focal point of contention, prompting direct intervention from Trump. External allies, such as pharmaceutical companies and anti-abortion organizations, also contributed to the growing dissatisfaction. These groups viewed Makary’s policies as a barrier to their interests, further fueling calls for his removal.

His leadership was further strained by the agency’s frequent leadership shifts. Over the past year, senior roles within the FDA saw constant turnover, creating instability and complicating policy implementation. Despite his efforts to streamline decision-making processes, Makary found himself at odds with various factions. This internal discord, combined with external pushback, led to a situation where his position became increasingly precarious.

Trump’s Confirmation and New Leadership

President Trump confirmed Makary’s exit and announced the appointment of Kyle Diamantas, his deputy commissioner in charge of the food program, as the acting FDA chief. The move was made public through a post on Truth Social, where Trump highlighted the decision. While Makary had previously attempted to reassure associates of his standing, the surprise announcement left him and his supporters scrambling to understand the rationale behind the action.

With Makary’s resignation, Trump now faces the task of filling another top post within the U.S. Health and Human Services Department. The search for a permanent FDA commissioner will require Senate approval, adding to the administration’s list of vacancies. Currently, the department lacks a confirmed CDC director and a permanent surgeon general, who typically holds the nation’s highest medical role. These gaps have raised concerns about the continuity of public health initiatives.

Kennedy’s Endorsement and the Search for a Replacement

Health and Human Services Secretary Robert F. Kennedy Jr. publicly endorsed Makary’s contributions in a post on X, stating: “The search for a new Commissioner is already underway, and we will move forward with urgency.” This praise contrasted with the internal criticism of Makary, though it underscored the administration’s awareness of the need to replace him swiftly.

“The search for a new Commissioner is already underway, and we will move forward with urgency.”

While some Trump aides worried about the political implications of replacing another high-ranking health official—especially ahead of the midterms—others saw it as a necessary step to realign the FDA with the administration’s priorities. The decision to appoint Diamantas as acting leader signals a shift toward stabilizing the agency and rebuilding relationships with key stakeholders in the anti-abortion movement and pharmaceutical sector.

Flavored E-Cigarettes and Policy Reversals

Makary’s resistance to approving flavored e-cigarettes became a critical issue in his tenure. The decision sparked intense debate, with Trump intervening directly to challenge his stance. Two insiders noted that the president grew frustrated with the FDA’s delayed action on the matter, leading to a broader push for Makary’s removal. Last week, the FDA reversed its position on flavored vape products, a move that came after internal pressure and external demands.

Although the reversal addressed immediate concerns, it also highlighted the fragility of Makary’s leadership. His efforts to maintain a balanced approach—supporting rapid drug approvals while cautioning against youth-appealing flavors—had drawn criticism from both sides. The administration’s focus on expediting regulatory decisions clashed with Makary’s emphasis on safety, particularly in the context of vaping’s health risks.

Testimony and Strategic Timing

Makary’s resignation occurs just days before he was scheduled to testify about the FDA’s proposed budget before the Senate Appropriations Committee. The timing of his departure has sparked questions about the administration’s strategic coordination. While the Senate was poised to hear his defense of the agency’s financial plans, the news of his exit has shifted the narrative, with lawmakers now questioning the urgency of his replacement.

Politico first reported Makary’s resignation, confirming that the decision had gained momentum in recent days. A faction of White House and HHS officials, disillusioned with the FDA’s chaotic operations, accelerated the process. They argued that the agency’s internal conflicts and policy ambiguities had undermined its effectiveness. Despite Makary’s attempt to secure Trump’s confidence, the president’s approval of his removal indicated a definitive end to his leadership.

Broader Implications and Restructuring

The potential restructuring of the FDA’s senior staff reflects the administration’s determination to address internal inefficiencies. With Makary’s departure, officials are considering overhauling the agency’s leadership framework to ensure alignment with Trump’s goals. This includes strengthening ties with the anti-abortion movement, which has long sought regulatory changes to limit access to certain medications, and bolstering the pharmaceutical industry’s influence over FDA decisions.

As the search for a new commissioner intensifies, the stakes for the administration are high. The Senate will need to prioritize confirming the next FDA chief, especially with the midterms approaching. This process may take significant time, potentially drawing attention away from other key issues. However, the appointment of Diamantas as acting leader is expected to provide a temporary solution while the permanent replacement is finalized.

Makary, a surgeon and author, had initially pledged to accelerate the FDA’s decision-making process following his confirmation in March 2025. His vision included expediting approvals for drugs, medical devices, and vaccines, but his tenure was marked by controversy. Pharmaceutical companies criticized his management of the drug approval process, while other administration officials questioned his handling of tobacco regulations and broader public health policies.

The e-cigarette dispute remains a central example of Makary’s challenges. His stance on flavored products, which had drawn both support and opposition, became a flashpoint for Trump and his advisers. The reversal of the FDA’s position on vapes underscores how internal pressure can force policy changes, even when a commissioner initially resisted. This shift highlights the administration’s ability to influence the FDA’s direction, despite Makary’s efforts to maintain independence.

In the wake of his resignation, the Trump administration faces the task of reshaping the FDA to better reflect its priorities. The leadership changes and policy adjustments will be critical in the lead-up to the November elections, as the agency aims to solidify its role in advancing the administration’s agenda. With Makary’s departure, the focus will now shift to finding a successor who can navigate the complex landscape of regulatory oversight and political expectations. This transition may signal a broader realignment of the HHS department’s priorities, ensuring alignment with the White House’s goals in the final stretch of the Trump presidency.